



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

June 16, 2022

Alexander Zwyer
Chief Executive Officer
NLS Pharmaceuticals Ltd.
The Circle 6
8058 Zurich, Switzerland

Re: NLS Pharmaceuticals Ltd.
Registration Statement on Form F-1
Filed June 10, 2022
File No. 333-265529

Dear Mr. Zwyer:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at (202) 551-3635 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Ron Ben-Bassat, Esq.